Immunotherapy against esophageal primary amelanotic malignant melanoma relapse
Abstract Melanoma is a malignant tumor derived from melanocytes. Esophageal melanomas occur infrequently, especially primary amelanotic malignant melanoma of the esophagus (PAMME), which is extremely rare. Here, we report the case of a 74-year-old man with an esophageal amelanotic melanoma on the es...
Gespeichert in:
Veröffentlicht in: | Journal of surgical case reports 2021-10, Vol.2021 (10) |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 10 |
container_start_page | |
container_title | Journal of surgical case reports |
container_volume | 2021 |
creator | Tsukamoto, Ryoichi Ihara, Hiroaki Takase, Masaru Shimazu, Ai Takei, Masahiko Miura, Hiroyoshi Sakamoto, Kazuhiro Namekata, Koji |
description | Abstract
Melanoma is a malignant tumor derived from melanocytes. Esophageal melanomas occur infrequently, especially primary amelanotic malignant melanoma of the esophagus (PAMME), which is extremely rare. Here, we report the case of a 74-year-old man with an esophageal amelanotic melanoma on the esophagogastric junction (EGJ) found on esophagogastroduodenoscopy. Radical surgery for the tumor at the EGJ was performed with total gastrectomy and D2 lymph node dissection. Diagnosis of PAMME was confirmed postoperatively by immunohistochemical staining. Four months after the surgery, abdominal computed tomography revealed multiple liver metastases. The patient received seven cycles of nivolumab monotherapy and two subsequent cycles of nivolumab and ipilimumab, and these metastases diminished. Recently, new therapeutic agents including immunotherapy have been developed for malignant melanoma and these agents have the potential of improving the prognosis of PAMME. Here, we present new insights into the diagnosis and therapeutic methods that can be used against primary esophageal melanoma. |
doi_str_mv | 10.1093/jscr/rjab393 |
format | Article |
fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8514264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jscr/rjab393</oup_id><sourcerecordid>10.1093/jscr/rjab393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-2acad73e44030f41a1b2501e08d87f9ecf43ca34feb8d9a27bf36962c99bc5b33</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbKm9-QNy82LsfiXZvQhS_CgUveh5md3spinZJOymgv_elBTRi3OZYd5nXoYXoWuC7wiWbLWPJqzCHjST7AzNKeY0FYLQ81_zDC1j3OOxuCRE5JdoxnieyYIVc_S68f7QdsPOBui_EqigbuOQ2Nj1O6gsNEkfag9hlLxtYCRrk3ho6qqFdkimnYckjEMf7RW6cNBEuzz1Bfp4enxfv6Tbt-fN-mGbGpbjIaVgoCyY5Rwz7DgBommGicWiFIWT1jjODDDurBalBFpox3KZUyOlNplmbIHuJ9_-oL0tjW2HAI06_ao6qNVfpa13quo-lcgIpzkfDW4nAxO6GIN1P7cEq2O06hitOkU74jcT3h36_8lv6p59dQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immunotherapy against esophageal primary amelanotic malignant melanoma relapse</title><source>Oxford Journals Open Access Collection</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Tsukamoto, Ryoichi ; Ihara, Hiroaki ; Takase, Masaru ; Shimazu, Ai ; Takei, Masahiko ; Miura, Hiroyoshi ; Sakamoto, Kazuhiro ; Namekata, Koji</creator><creatorcontrib>Tsukamoto, Ryoichi ; Ihara, Hiroaki ; Takase, Masaru ; Shimazu, Ai ; Takei, Masahiko ; Miura, Hiroyoshi ; Sakamoto, Kazuhiro ; Namekata, Koji</creatorcontrib><description>Abstract
Melanoma is a malignant tumor derived from melanocytes. Esophageal melanomas occur infrequently, especially primary amelanotic malignant melanoma of the esophagus (PAMME), which is extremely rare. Here, we report the case of a 74-year-old man with an esophageal amelanotic melanoma on the esophagogastric junction (EGJ) found on esophagogastroduodenoscopy. Radical surgery for the tumor at the EGJ was performed with total gastrectomy and D2 lymph node dissection. Diagnosis of PAMME was confirmed postoperatively by immunohistochemical staining. Four months after the surgery, abdominal computed tomography revealed multiple liver metastases. The patient received seven cycles of nivolumab monotherapy and two subsequent cycles of nivolumab and ipilimumab, and these metastases diminished. Recently, new therapeutic agents including immunotherapy have been developed for malignant melanoma and these agents have the potential of improving the prognosis of PAMME. Here, we present new insights into the diagnosis and therapeutic methods that can be used against primary esophageal melanoma.</description><identifier>ISSN: 2042-8812</identifier><identifier>EISSN: 2042-8812</identifier><identifier>DOI: 10.1093/jscr/rjab393</identifier><identifier>PMID: 34659737</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Case Report</subject><ispartof>Journal of surgical case reports, 2021-10, Vol.2021 (10)</ispartof><rights>Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2021. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-2acad73e44030f41a1b2501e08d87f9ecf43ca34feb8d9a27bf36962c99bc5b33</citedby><cites>FETCH-LOGICAL-c360t-2acad73e44030f41a1b2501e08d87f9ecf43ca34feb8d9a27bf36962c99bc5b33</cites><orcidid>0000-0002-1225-6930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514264/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514264/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1598,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Tsukamoto, Ryoichi</creatorcontrib><creatorcontrib>Ihara, Hiroaki</creatorcontrib><creatorcontrib>Takase, Masaru</creatorcontrib><creatorcontrib>Shimazu, Ai</creatorcontrib><creatorcontrib>Takei, Masahiko</creatorcontrib><creatorcontrib>Miura, Hiroyoshi</creatorcontrib><creatorcontrib>Sakamoto, Kazuhiro</creatorcontrib><creatorcontrib>Namekata, Koji</creatorcontrib><title>Immunotherapy against esophageal primary amelanotic malignant melanoma relapse</title><title>Journal of surgical case reports</title><description>Abstract
Melanoma is a malignant tumor derived from melanocytes. Esophageal melanomas occur infrequently, especially primary amelanotic malignant melanoma of the esophagus (PAMME), which is extremely rare. Here, we report the case of a 74-year-old man with an esophageal amelanotic melanoma on the esophagogastric junction (EGJ) found on esophagogastroduodenoscopy. Radical surgery for the tumor at the EGJ was performed with total gastrectomy and D2 lymph node dissection. Diagnosis of PAMME was confirmed postoperatively by immunohistochemical staining. Four months after the surgery, abdominal computed tomography revealed multiple liver metastases. The patient received seven cycles of nivolumab monotherapy and two subsequent cycles of nivolumab and ipilimumab, and these metastases diminished. Recently, new therapeutic agents including immunotherapy have been developed for malignant melanoma and these agents have the potential of improving the prognosis of PAMME. Here, we present new insights into the diagnosis and therapeutic methods that can be used against primary esophageal melanoma.</description><subject>Case Report</subject><issn>2042-8812</issn><issn>2042-8812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kE1Lw0AQhhdRbKm9-QNy82LsfiXZvQhS_CgUveh5md3spinZJOymgv_elBTRi3OZYd5nXoYXoWuC7wiWbLWPJqzCHjST7AzNKeY0FYLQ81_zDC1j3OOxuCRE5JdoxnieyYIVc_S68f7QdsPOBui_EqigbuOQ2Nj1O6gsNEkfag9hlLxtYCRrk3ho6qqFdkimnYckjEMf7RW6cNBEuzz1Bfp4enxfv6Tbt-fN-mGbGpbjIaVgoCyY5Rwz7DgBommGicWiFIWT1jjODDDurBalBFpox3KZUyOlNplmbIHuJ9_-oL0tjW2HAI06_ao6qNVfpa13quo-lcgIpzkfDW4nAxO6GIN1P7cEq2O06hitOkU74jcT3h36_8lv6p59dQ</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Tsukamoto, Ryoichi</creator><creator>Ihara, Hiroaki</creator><creator>Takase, Masaru</creator><creator>Shimazu, Ai</creator><creator>Takei, Masahiko</creator><creator>Miura, Hiroyoshi</creator><creator>Sakamoto, Kazuhiro</creator><creator>Namekata, Koji</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1225-6930</orcidid></search><sort><creationdate>20211001</creationdate><title>Immunotherapy against esophageal primary amelanotic malignant melanoma relapse</title><author>Tsukamoto, Ryoichi ; Ihara, Hiroaki ; Takase, Masaru ; Shimazu, Ai ; Takei, Masahiko ; Miura, Hiroyoshi ; Sakamoto, Kazuhiro ; Namekata, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-2acad73e44030f41a1b2501e08d87f9ecf43ca34feb8d9a27bf36962c99bc5b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsukamoto, Ryoichi</creatorcontrib><creatorcontrib>Ihara, Hiroaki</creatorcontrib><creatorcontrib>Takase, Masaru</creatorcontrib><creatorcontrib>Shimazu, Ai</creatorcontrib><creatorcontrib>Takei, Masahiko</creatorcontrib><creatorcontrib>Miura, Hiroyoshi</creatorcontrib><creatorcontrib>Sakamoto, Kazuhiro</creatorcontrib><creatorcontrib>Namekata, Koji</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of surgical case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsukamoto, Ryoichi</au><au>Ihara, Hiroaki</au><au>Takase, Masaru</au><au>Shimazu, Ai</au><au>Takei, Masahiko</au><au>Miura, Hiroyoshi</au><au>Sakamoto, Kazuhiro</au><au>Namekata, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy against esophageal primary amelanotic malignant melanoma relapse</atitle><jtitle>Journal of surgical case reports</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>2021</volume><issue>10</issue><issn>2042-8812</issn><eissn>2042-8812</eissn><abstract>Abstract
Melanoma is a malignant tumor derived from melanocytes. Esophageal melanomas occur infrequently, especially primary amelanotic malignant melanoma of the esophagus (PAMME), which is extremely rare. Here, we report the case of a 74-year-old man with an esophageal amelanotic melanoma on the esophagogastric junction (EGJ) found on esophagogastroduodenoscopy. Radical surgery for the tumor at the EGJ was performed with total gastrectomy and D2 lymph node dissection. Diagnosis of PAMME was confirmed postoperatively by immunohistochemical staining. Four months after the surgery, abdominal computed tomography revealed multiple liver metastases. The patient received seven cycles of nivolumab monotherapy and two subsequent cycles of nivolumab and ipilimumab, and these metastases diminished. Recently, new therapeutic agents including immunotherapy have been developed for malignant melanoma and these agents have the potential of improving the prognosis of PAMME. Here, we present new insights into the diagnosis and therapeutic methods that can be used against primary esophageal melanoma.</abstract><pub>Oxford University Press</pub><pmid>34659737</pmid><doi>10.1093/jscr/rjab393</doi><orcidid>https://orcid.org/0000-0002-1225-6930</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2042-8812 |
ispartof | Journal of surgical case reports, 2021-10, Vol.2021 (10) |
issn | 2042-8812 2042-8812 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8514264 |
source | Oxford Journals Open Access Collection; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Case Report |
title | Immunotherapy against esophageal primary amelanotic malignant melanoma relapse |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A41%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20against%20esophageal%20primary%20amelanotic%20malignant%20melanoma%20relapse&rft.jtitle=Journal%20of%20surgical%20case%20reports&rft.au=Tsukamoto,%20Ryoichi&rft.date=2021-10-01&rft.volume=2021&rft.issue=10&rft.issn=2042-8812&rft.eissn=2042-8812&rft_id=info:doi/10.1093/jscr/rjab393&rft_dat=%3Coup_pubme%3E10.1093/jscr/rjab393%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34659737&rft_oup_id=10.1093/jscr/rjab393&rfr_iscdi=true |